Intraductal carcinoma of the prostate (IDC-P) is a distinct tumor type characterized by an expansile growth of atypical glandular epithelial cells within pre-existing prostate glands and ducts and has significant implications on clinical outcomes and patient management. There is an agreement that isolated IDC-P should not be graded, and IDC-P should be reported with a comment on its clinical significance. However, whether IDC-P should be factored into Grade Group (GG) in the presence of concurrent prostate cancer (PCa) has been debated vigorously. The contradicting opinions were promulgated when the Genitourinary Pathology Society (GUPS) and the International Society of Urological Pathologists (ISUP) published their recommendations for this issue. When IDC-P is present with PCa, the ISUP recommends incorporating it in the GG for the entire case, whereas the GUPS recommends excluding it from the final GG. Consequently, pathologists and clinicians are faced with the conundrum of conflicting recommendations. In this review article, the authors evaluate the magnitude of discrepant GG between the two grading methods, explore the rationales behind the differing views of the two urological societies, present the current reporting practices for IDC-P, and propose a provisional and pragmatic guide to alleviate the dilemma of which recommendation to follow.
We present a case of leiomyosarcoma arising from the renal pelvis, which is a rare clinical entity. A percutaneous endoscopic resection led to the final histopathological diagnosis. The patient underwent radical nephrectomy and did not receive adjuvant therapy. Based on follow-up CT scans, he remains recurrence-free one year after surgery.
7 December 2025 in American Journal of Case Reports
BACKGROUND Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become important in the treatment of diabetic kidney disease (DKD). Despite their reno-protective effect, kidney injury from GLP-1 RAs has been rarely reported. The reported kidney injuries varied from mild symptoms to dialysis at presentation and occurred 2 days to 2 years after drug initiation. We report a case of a patient with DKD who developed an episode of interstitial nephritis after dulaglutide administration. CASE REPORT A 63-year-old woman with stage 3b diabetic kidney disease and depressive disorder was prescribed dulaglutide 0.75 mg/week subcutaneously in August 2023 due to persistent albuminuria despite receiving the maximum tolerated dose of azilsartan. Sodium-glucose cotransporter-2 inhibitor was not prescribed in this case due to her frequent urinary tract infections. Serum creatinine at 2-month follow-up increased and then doubled despite reduction in the azilsartan dose. Potentially nephrotoxic medications were discontinued and no other possible causes of kidney injury, including volume depletion, were presented. Kidney biopsy revealed active interstitial nephritis and diabetic nephropathy without accumulation of immune complex. After discontinuing dulaglutide, there was an almost complete recovery of kidney function without steroid therapy. Azilsartan and chlorthalidone could then be successfully rechallenged. CONCLUSIONS Despite the established renoprotective effect of GLP-1 RAs, acute-to-chronic tubulointerstitial nephritis occasionally occurs, requiring vigilant monitoring after drug initiation or titration. Nevertheless, this does not prevent the prescription of GLP-1 RAs to alleviate DKD progression in certain patients. Treatment includes drug discontinuation and steroid therapy in non-responders.